fda warning letter glp-1 october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our fda glp-1 enforcement news october

The analysis found semaglutide drugs like Ozempic increased the risk of DVT by 266%

I heard back in like 20 minutes. The Greenwood mom paid $800 for a 6-month supply of semaglutide

This blog is for informational purposes only and does not constitute medical advice

The patient did not take any other medications during the three months before starting BGM0504, during the period of receiving the four injections, or in the three weeks following the fourth injection, until the onset of his illness (Table 1)

The study revealed that use of semaglutide was associated with a 42% lower risk of worsening mental illness compared to periods when the same individuals were not taking GLP-1 receptor agonists

Employers should consider requiring documented diagnoses, evidence-based prior authorization, and stepped therapy, plus lifestyle programs before approving GLP-1s for weight loss to curb long-term spend